Alexion

Author: Magicure Date: 2022-09-09

Alexion Pharmaceuticals is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases. It became a subsidiary of AstraZeneca in 2021.

Alexion Pharmaceutical

Alexion's first drug, Soliris (Eculizumab), launched in 2007, used to treat atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). It has been approved for use in Canada, the European Union, Japan, and the United States.

In September 2011, the FDA approved the use of Soliris as a treatment for atypical hemolytic-uremic syndrome in both adults and children.

In October 2017, the FDA approved the use of Soliris to treat adult patients with generalized myasthenia gravis (gMG). In November 2017, the company received a patent for Soliris from the Japan Patent Office.

Last：Amgen

Next：HRA Pharma

Disclaimer: The services of Hong Kong Magicure Medical Center do not replace a physician-patient relationship and are not intended as medical advice. Hong Kong Magicure Medical Center provides patients and physicians with new medicine options by providing safe and secure access to approved medicines from other countries. We only provide this service after the patient and physician have made a professional decision on the treatment.

Alexion

Soliris (Eculizumab)

Prestige Biopharma Receives FDA

Selective BRAF Inhibitor Gets O

Phase 3 trial of Dupixent (dupi

Eisai

NEJM：Inaxaplin in the treatme

Novartis Tafinlar+Mekinist comb

Label Expansion for LIVMARLI in

Significant improvement in skin

Magicure

Our Services

Links

Follow us